Intercept Pharmaceuticals, Inc.
ICPTDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Obeticholic acid (10 mg)
Compensated Cirrhosis
Obeticholic Acid (OCA)
Primary Biliary Cirrhosis
INT-747
Diabetes Mellitus, Type II
INT-787
Alcohol Associated Hepatitis
Obeticholic Acid
Primary Biliary Cirrhosis
Bezafibrate 100 mg
Primary Biliary Cholangitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obeticholic acid (10 mg) | Phase 3 | Compensated Cirrhosis | - | - |
Obeticholic Acid (OCA) | Phase 3 | Primary Biliary Cirrhosis | - | - |
INT-747 | Phase 2 | Diabetes Mellitus, Type II | - | - |
INT-787 | Phase 2 | Alcohol Associated Hepatitis | - | - |
Obeticholic Acid | Phase 2 | Primary Biliary Cirrhosis | - | - |
Bezafibrate 100 mg | Phase 2 | Primary Biliary Cholangitis | - | - |
Frequently asked questions
What is in Intercept Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Intercept Pharmaceuticals, Inc.'s (ICPT) pipeline across Phase 3, Phase 2. Its lead program is Obeticholic acid (10 mg) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intercept Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Intercept Pharmaceuticals, Inc. (ICPT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ICPT biotech catalysts?→
Add ICPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intercept Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.